Overall rank by patents
#21,178
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Guangdong Raynovent Biotech Co., Ltd.
USPTO PatentsView assignee record - 13 granted patents across 7 technology areas, active 2019–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
13
Total patents granted
7
CPC technology areas
16.6
Avg claims per patent
+450%
5-year filing velocity
The verdict
Guangdong holds 13 US patents across 7 technology areas, rank #21,178 of 50,000 tracked assignees.
- #21,178
- of 50,000 US assignees by volume
- Top 59%
- by Innovation Score (32.3/100)
- 16.6
- avg claims per patent
- +450%
- filing velocity, last 5 yrs
Portfolio overview
Guangdong Raynovent Biotech Co., Ltd. has been granted 13 US utility patents between 2019 and 2025, placing Guangdong Raynovent Biotech Co., Ltd. at rank #21,178 across all assignees tracked by PlainPatent. This portfolio spans 7 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.6 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Guangdong Raynovent Biotech Co., Ltd. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 32.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 11 grants, compared with 2 in the 2015–2019 window, a +450% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Guangdong Raynovent Biotech Co., Ltd.'s 16.6 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 7 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Guangdong Raynovent Biotech Co., Ltd. against peers pursuing similar technology classes.
How does Guangdong compare?
Granted US patents 2015–2025 versus the largest corporate holders, this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- Guangdong Raynove… ◀ 13
GUANGDONG RAYNOVENT BIOTECH CO., LTD.
13 patents
What this shows Guangdong holds 13 patents, placing it at rank #21,178 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
Guangdong's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
32 Top 59% higher than 41% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2019–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 2 | 15.4% |
| 2020 | 4 | 30.8% |
| 2021 | 1 | 7.7% |
| 2022 | 3 | 23.1% |
| 2023 | 1 | 7.7% |
| 2025 | 2 | 15.4% |
Which technologies does Guangdong Raynovent Biotech Co., Ltd. patent most?
Top 7 of 7 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Accelerating
Frequently Asked Questions
How many patents does Guangdong Raynovent Biotech Co., Ltd. hold?
Guangdong Raynovent Biotech Co., Ltd. holds 13 US granted patents filed between 2019 and 2025, spanning 7 technology areas.
What is Guangdong Raynovent Biotech Co., Ltd.'s Innovation Score?
Guangdong Raynovent Biotech Co., Ltd. has an Innovation Score of 32.3 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Guangdong Raynovent Biotech Co., Ltd. focus on?
Guangdong Raynovent Biotech Co., Ltd.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 12 patents. The company has filed patents in 7 CPC subclasses total.
Is Guangdong Raynovent Biotech Co., Ltd.'s patent filing rate increasing or decreasing?
Guangdong Raynovent Biotech Co., Ltd.'s recent filing velocity is +450% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Guangdong Raynovent Biotech Co., Ltd.'s patents?
Guangdong Raynovent Biotech Co., Ltd.'s patents average 16.6 claims each. This falls within the standard range, providing solid legal coverage.
How is the Guangdong Raynovent Biotech Co., Ltd. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Guides to patent portfolio analysis
How to use this portfolio
Guangdong's 13 grants land it in the top 59% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Guangdong ranks #21,178 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Explore the patent dataset
A61P technology
Guangdong Raynovent Biotech Co., Ltd.'s primary CPC class, all holders and yearly trends
Top 50 patent holders
See where Guangdong Raynovent Biotech Co., Ltd. ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Data sources used on this page
- USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
- Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
- USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.